SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Belanger who wrote (986)6/11/1997 10:53:00 PM
From: Roger Cranwill   of 1762
 
Again, the Coulter drug was discussed at the annual meeting (I say again only because I've brought up the meeting before). As has been brought up in this thread, Mr Rastetter stated that Coulter's product had some drawbacks, in that the patient will probably require hospitalization till radiation levels would be acceptable.
This hospitalization would really drive up the cost of the use of the drug, and would figure into the decisions as to usage. Of the alternatives, CHOP, treatment with Coulter's drug, and C2B8, I would think that C2B8 would be the regimen preferred by both the oncologist and the patient, with quality of life being a major factor in the determination.
Roger
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News